For Ten Years the Mayo Clinic has Assisted in Product Development for Biosig’s Pure EP System. Now the Revenues have Begun.

For Ten Years the Mayo Clinic has Assisted in Product Development for Biosig’s Pure EP System. Now the Revenues have Begun.

BioSig (BSGM) Revenues have started kicking in now let’s look at where sales of Pure EP could realistically take the market cap of this company.

Good day everyone,

We are continuing our coverage on BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace.

Current price $5.12 per share

After opening at $4.55 BSGM shares closed yesterday’s session at $5.12/share (+13.53%). The high of the day was $5.44, up 20% in mid-day trading. Trading volume was 1.2 million shares exceeding the daily average by a factor of 3.1X.

PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP room.

Atrial fibrillation is the leading indication segment in the electrophysiology devices market in terms of revenue. It is a common type of arrhythmia associated with a high risk of stroke and blood clotting. Afib is a condition affecting many including Gene Simmons, Elton John, Miley Cyrus, Howie Mandel, and yes, Joe Biden (hope Walter Reed has a PURE EP System).

Sudden Cardiac Arrest due to abnormal heart rhythm is one of the major reasons for deaths in western countries. It affects approximately 1 in 1000 inhabitants per year.

Yesterday, we broke the news to you that BSGM completed the first commercial sales of their PURE EP System. It’s a milestone that could propel the company into growing revenues and a higher share price.

There are 7,340 EP rooms at hospitals across the globe and 3,425 of them are in the USA. Each one of those EP rooms is a candidate for a PURE EP System. BSGM has units installed at less than 10 of those EP Rooms. The Mayo Clinic has it, they’ve been working with BioSig on product development for ten years.

The global electrophysiology devices market size was valued at 5.1 billion in 2018 and is expected to rise to $10.61 billion in 2025 indicating a CAGR of 9.6%. Increasing use of electrophysiology devices in the diagnosis and treatment of cardiovascular diseases such as atrial fibrillation will drive that growth.

The market is highly competitive with companies such as Boston Scientific Corporation, Medtronic Plc., Abbot Laboratories, and Biosense Webster, Inc. Biotronik SE & Co. KG., GE Healthcare, and Siemens Healthcare all involved.

Boston Scientific boosted its presence in the EP sector with the acquisition of privately held Apama Medical for $300 million.

The company has been awarded 5 patents and eleven additional worldwide utility patent applications are pending covering various aspects of its PURE EP System.

BSGM will generate revenues from PURE EP Systems on two levels. The first would be the sale of the actual hardware and the second will be for software, software updates, maintenance, and other charges to customers in the form of a contract.

BSGM has about 60 PURE EP Systems in inventory, already paid for. The PURE EP System units sell for $250,000 each with additional revenues from software and product support. Cardiac operating rooms can cost up to $20 million to equip and with the defined advantages of PURE EP, the cost of the units could be easily justified.

If we do the math, with 7,340 EP rooms across the world as potential customers and a potential sale price of $250,000 we arrive at $1.8 billion and that would just be hardware sales. We don’t expect every EP room in the world to get a Pure EP system. But, if BSGM penetrated just 10% of the USA EP rooms per year (342 units), along with software support, they could realistically reach $100 million in annual revenue.

A biotech company with $100M in revenue trading at just 3.0X revenues, in the case of BSGM that would be $9.77 per share. The 2 analysts offering 12-month price forecasts for BioSig Technologies Inc have a median target of $10.63, with a high estimate of $13.00 and a low estimate of $8.25.

BSGM shares could have a good upward move near term.

Stay tuned and stay informed,
The Traders News Group


Our Previous report on Biosig


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s sister company (SCS LLC) has been compensated twenty one thousand five hundred dollars cash via bank wire by legends media llc for this week’s coverage of bsgm. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.